This website is intended for healthcare professionals.

FERACCRU® had a consistently good tolerability profile1,2

Fewer than 1 in 4 patients had treatment-related AEs during long-term treatment2

AEs were mainly mild to moderate in severity and gastrointestinal in nature1,2

Just 7% of patients discontinued FERACCRU® due to treatment-related AEs2

FERACCRU® was well tolerated throughout long-term treatment despite 2/3 patients previously failing with oral ferrous iron salts due to AEs1,2

Study design

FERACCRU® had no negative impact on patients’ QoL or IBD severity1,2

AE, adverse event; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CKD, chronic kidney disease; Hb, haemoglobin; IBD, inflammatory bowel disease; IDA, iron deficiency anaemia; QoL, quality of life; SCCAI, Simple Clinical Colitis Activity Index; TSAT, transferrin saturation; UC, ulcerative colitis.


  1. Gasche C, et al. Inflamm Bowel Dis 2015;21(3):579–588.
  2. Schmidt C, et al. Aliment Pharmacol Ther 2016;44(3):259–270.